Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Lilly的Zepbound(Tirzepatide)在一对一的试验中,平均体重减轻20.2%,明显优于Wegovy(Semaglutide)的13.7%
Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Lilly的Zepbound(Tirzepatide)在一对一的试验中,平均体重减轻20.2%,明显优于Wegovy(Semaglutide)的13.7%
使用浏览器的分享功能,分享给你的好友吧